cjc 1295 with retatrutide ipamorelin Current research stack: CJC-1295/Ipamorelin, Retatrutide, GHK-Cu, and Melanotan II. Each one targets something different in the body: • CJC-1295 + Ipamorelin – supports cjc 1295 dac with ipamorelin

Horowitz M, Flint A, Doran S, Rasmussen MF, Kapitza C, Andreasen AH et al

Comorbidities: Type 2 diabetes: Both are FDA-approved for diabetes (tirzepatide as Mounjaro, semaglutide as Ozempic) Cardiovascular disease: Semaglutide has the cardiovascular outcomes data Sleep apnea: Tirzepatide has shown benefits Injection frequency: Both are once-weekly

It has also been suggested that GLP-1RAs may affect alcohol misuse and withdrawal symptoms by modulating anxiogenic mechanisms in rats 73

This pattern is consistent with broader GLP-1 research showing women achieving approximately 11 percent greater relative weight loss than men across studies

It has not received FDA approval for any indication

By September 2023, an astounding nine million Ozempic prescriptions had been written